Amit S Khot

18PUBLICATIONS
95CO-AUTHORS
Molecular targetsGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Radiation therapyInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Aug 25, 2026
Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.

|Mar 02, 2026
Efficacy and Safety of Belantamab Mafodotin with Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: The DREAMM-6 Arm B Trial.

Rakesh Popat, Bradley Augustson, Paul Cannell

|Dec 23, 2025
Establishing Barriers to and Enablers of Nurse-Enabled Subcutaneous Therapy Self-Administration Programs for Patients With Myeloma: Protocol for a Qualitative Descriptive Study.

Hayley Beer, Lisa Guccione, Amit Khot

|Dec 11, 2025
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.

Sasanka M Handunnetti, Amit Khot, Piers Blombery

|Aug 14, 2025
Ribosome Biogenesis and Function in Cancer: From Mechanisms to Therapy.

Kezia Gitareja, Shalini S Chelliah, Elaine Sanij

|Jul 02, 2025
Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial.

Victoria G Hall, Thi H O Nguyen, Olivia C Smibert

Pageof 3

Frequent Collaborators

3 joint publications

Stephen Lade

3 joint publications

Simon J Harrison

3 joint publications

John F Seymour

2 joint publications

Michelle K Yong